ArticleCommunications biology2025
CD28-mediated linear and parallel costimulatory signaling cooperatively regulate CAR-T cell functions via CAR-CD28 microclusters.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models.Blood cancer discovery · 2026Article
- Discovery of co-stimulatory anti-CD28 VHHs for developing cancer immune therapeutic anti-tumor/CD3/CD28 trispecific T cell engager.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Various improvements have been made to chimeric antigen receptor (CAR)-T cells to enhance their antitumor effects and expand their indications to various cancer types. Although second-generation CARs directly induce second signals in a linear pathway via their own costimulatory domain such as CD28, CAR-T cells themselves express costimulatory receptors, which induce additional second signals in parallel. To clarify the differences between these two types of second signals, we here reveal CD28-mediated signalosomes using high-resolution imaging. CAR constructed using CD3ζ and CD28 (CD28ζ.CAR)-T cells demonstrate intense and persistent accumulation of the CD28 downstream kinase protein kinase C θ (PKCθ) at CAR signalosomes, and endogenous CD28 on CAR-T cells prolongs the CD28-CAR association. This assembling of PKCθ is correlated with IL-2 production and in vivo tumor suppression by CAR-T cells. These results indicate that the development and improvement of CARs requires analysis of intrinsic T-cell responses, which can be effectively assessed from signalosome dynamics evaluated by molecular imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.